Tekmira Initiating Phase I/II Clinical Trial in Patients with Hepatocellular Carcinoma
27 mai 2014 09h10 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 27, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs
21 mai 2014 12h34 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Provides Corporate Update and Announces First Quarter 2014 Results
14 mai 2014 16h26 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Reports on Voting Results From 2014 Annual Meeting of Shareholders
09 mai 2014 17h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 9, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced the...
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results
07 mai 2014 18h45 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 7, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Tekmira's Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02)
28 avr. 2014 18h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 28, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Presents Advances in Anti-Viral Product Platform at Scientific Symposium
01 avr. 2014 10h25 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 1, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Announces Completion of Underwritten Public Offering of Common Stock
18 mars 2014 13h53 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 18, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Announces Pricing of Underwritten Public Offering of Common Stock
13 mars 2014 07h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 13, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Announces Proposed Public Offering of Common Stock
10 mars 2014 16h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 10, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...